SaNOtize, Lupin In Legal Row Concerning COVID-19 Nasal Spray
Executive Summary
Canada-based biotech firm SaNOtize and Lupin battle it out in court over alleged breach of confidentiality and copyright infringement in a case concerning their nitric oxide nasal spray for COVID-19.
You may also be interested in...
Canadian Firm Explores Potential Of Nasal Spray In COVID-19 Prevention
Dr Gilly Regev, CEO of the anti-infectives-focused firm, SaNOtize Research & Development Corp, remains confident of the effectiveness of the firm’s nitric oxide nasal spray against evolving variants of SARS-CoV-2 and expects to progress plans for a “prevention” trial in the US.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Lynparza poised for expansion in prostate cancer; zuranolone faces challenges in depression; Novartis transfers products and cuts jobs in India; US call to build Alzheimer’s infrastructure; and Indian legal row over COVID spray product.
Life Sciences Scaling Adoption Of New Metaverse, AI Tools
Life sciences firms are increasingly adopting new technologies like the metaverse and piloting use cases, although a "truly 3D immersive customer experience" may be some distance away. But 2024 could see an inflection point with increasing demand for certain metaverse applications, says a senior Indegene executive.